Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 46.6 kDa. The protein migrates as 60-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human Axl, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Human Axl, His Tag (Cat. No. AXL-H5226) immobilized on CM5 Chip can bind Human GAS6, His Tag (Cat. No. GA6-H5249) with an affinity constant of 3.4 nM as determined in SPR assay (Biacore 8K) (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Gilteritinib Fumarate | ASP-2215; 66D-92MGC8M (UNII code); ASP-2215 hemifumarate | Approved | Astellas Pharma Inc | Xospata | Mainland China | Leukemia, Myeloid, Acute | Astellas Pharmaceutical (China) Co Ltd | 2018-09-21 | Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | Japan | Carcinoma, Renal Cell | Takeda | 2012-11-29 | Osteosarcoma; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Astrocytoma; Breast Neoplasms; Sarcoma, Ewing; Lymphoma; Carcinoma, Adenosquamous; Adenocarcinoma, Clear Cell; Sarcoma, Clear Cell; Medullary thyroid cancer (MTC); Cholangiocarcinoma; Prostatic Neoplasms; Neurofibroma, Plexiform; Urethral Neoplasms; Carcinoma, Neuroendocrine; Meningioma; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Melanoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Neuroblastoma; Glioma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Fallopian Tube Neoplasms; Carcinoid Tumor; Neurofibromatoses; Seminoma; Carcinoma, Transitional Cell; Glioblastoma; Rejection of liver transplantation; Carcinoma, Merkel Cell; Hepatoblastoma; Pain; Pheochromocytoma; Neoplasms; Carcinoma, Renal Cell; B | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms | Details |
AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | Details |
NP-107 | NP107; NP-107 | Phase 1 Clinical | Shanghai Nawei Biotechnology Co Ltd | Solid tumours | Details |
BPI-9016 | BPI-9016; BPI-9016M | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
ONO-7475 | ONO-7475 | Phase 2 Clinical | Ono Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
Tilvestamab | BGB-149 | Phase 1 Clinical | Bergenbio | Ovarian Neoplasms | Details |
Enapotamab vedotin | AXL-107-MMAE | Phase 2 Clinical | Seattle Genetics Inc, Genmab A/S | Ovarian Neoplasms; Sarcoma; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma | Details |
XZB-0004 | SLC-391; XZB-0004 | Phase 1 Clinical | Solid tumours; Hematologic Neoplasms; Foodborne Diseases; Carcinoma, Non-Small-Cell Lung | Details | |
Butylidenephthalide | HK-001; LF-001 (Everfront Biotech); NSC-325307; BDPH | Phase 2 Clinical | Everfront Biotech Co Ltd | Glioma; Amyotrophic Lateral Sclerosis | Details |
Glesatinib | 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265; MG-90265X; MGCD-265 | Phase 2 Clinical | Mirati Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
INCB-081776 | INCB-81776; INCB-081776 | Phase 1 Clinical | Incyte Corp | Solid tumours; Neoplasms | Details |
Dubermatinib | TP-0903 | Phase 2 Clinical | Sumitomo Dainippon | Ovarian Neoplasms; Solid tumours; Neoplasms; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Bemcentinib | R-428; BGB-324 | Phase 2 Clinical | Rigel Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19); Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms; Myelodysplastic Syndromes; Adenocarcinoma of Lung; Pancreatic Neoplasms; Mesothelioma; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
KC1036 | KC1036; KC-1036 | Phase 2 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Digestive System Neoplasms; Neoplasm Metastasis | Details |
Q-702 | Q-702 | Phase 2 Clinical | Qurient Co Ltd | Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis; Uterine Cervical Neoplasms | Details |
FC-084-CSA | FC-084-CSA; FC084CSA | Phase 1 Clinical | Zhongshan Yinuo Weishen New Drug Research and Development Co Ltd | Solid tumours | Details |
PF-07265807 | PF-07265807 | Phase 1 Clinical | Solid tumours; Neoplasm Metastasis | Details | |
TT-00973 | TT-00973 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours | Details |
HH-30134 | HH-30134 | Phase 1 Clinical | ShangHai HaiHe Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
CCT301-38 | CCT301-38; CCT301-38 AXL | Phase 2 Clinical | F1 Oncology, Bioatla | Carcinoma, Renal Cell; Rhinitis, Allergic, Seasonal | Details |
Mipasetamab uzoptirine | ADCT-601; BGB-601 | Phase 1 Clinical | Adc Therapeutics Sa | Solid tumours; Neoplasms | Details |
Mecbotamab vedotin | BA-3011; BA3011; BA 3011 | Phase 2 Clinical | Bioatla | Solid tumours; Leiomyosarcoma; Ovarian Neoplasms; Sarcoma, Synovial; Liposarcoma; Sarcoma; Osteosarcoma; Sarcoma, Ewing; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
This web search service is supported by Google Inc.